EVGN

$0.87

Post-MarketAs of Mar 17, 8:00 PM UTC

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$0.87
Potential Upside
5%
Whystock Fair Value$0.92
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, in...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.02M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-100.69%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.31

Recent News

GuruFocus.com
Mar 14, 2026

Evogene Ltd (EVGN) Q4 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue Decline

Despite a drop in revenue, Evogene Ltd (EVGN) focuses on AI-driven innovations and strategic partnerships to enhance future growth prospects.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 6, 2026

Evogene Ltd. Q4 2025 Earnings Call Summary

Moby summary of Evogene Ltd.'s Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Associated Press Finance
Mar 5, 2026

Evogene: Q4 Earnings Snapshot

REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $5.3 million in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had a loss of 61 cents. The agricultural company posted revenue of $314,000 in the period.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
Nov 20, 2025

Evogene: Q3 Earnings Snapshot

REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported profit of $3.9 million in its third quarter. The Rehovot, Israel-based company said it had profit of 44 cents per share. Losses, adjusted to account for discontinued operations, came to 31 cents per share.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Aug 24, 2025

Evogene Declares The Sale Of Lavie Bio’s Activity To ICL Completed

ICL Group Ltd (NYSE:ICL) is among the 13 Best Magnesium Stocks to Invest in Now. Evogene Ltd. announced the successful sale of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd (NYSE:ICL). The acquisition, which was first revealed on April 21, 2025, comprises Lavie Bio’s patented Biology Driven Design technology platform, microbial bank, pipeline […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.